GCP
FRTX

GSA Capital Partners’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

GSA Capital Partners’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,527
Closed -$179K – 1902
2021
Q3 		$179K Buy
+5,527
New +$179K 0.02% 1258

Other funds holding FRTX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

GSA Capital Partners's FRTX Position: Q4 2021 in Review

GSA Capital Partners sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q4 2021, closing a stake of 5,527 shares — an estimated $179K sold.

GSA Capital Partners first reported a position in FRTX in Q3 2021 and held it in 1 quarter. The position peaked at $179K in Q3 2021. 30 funds tracked by Wall St. Rank hold FRTX as of Q4 2021.

  • GSA Capital Partners reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • GSA Capital Partners sold 5,527 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $179K.
  • GSA Capital Partners first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • GSA Capital Partners's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $179K in Q3 2021.
  • 30 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q4 2021.

Based on GSA Capital Partners's 13F filing for Q4 2021, filed 14 Feb 2022.